Authors
Dona Susan Mathewa, Ganga Rajua, Ivy Vishvamohanana, Ashish Jitendranatha, Ramani Baia
Abstract
Stenotrophomonas maltophilia is an emerging nosocomial pathogen that causes fatal infections in critically ill or immunocompromised patients. S.maltophilia bacteremia (SMB) is a rare condition and is assosciated with morbidity and mortality, and its optimal management remains ill defined. The aim of the current study is to review the management of S.maltophilia bacteremia1. We described five cases of S.maltophilia bacteremia in immunocompromised patients over a period of 6 months from September 2019 to February 2020. In the current review, a few cases had undergone surgical intervention prior to the onset of bacteremia. Prolonged antibiotic therapy (eg carbapenam), healthcare exposure , and prior surgical procedures were the major risk factors associatd with S. maltophilia infection in healthcare settings. Optimal therapy is based on antimicrobial sensitivity , and the trimethoprim-sulfamethoxazole based combination has been shown to be successful.